D-0701-2021 Class II Ongoing

Recalled by Pfizer Inc. — New York, NY

FDA drug recall D-0701-2021 was initiated by Pfizer Inc. on Jun 9, 2021 and is designated Class II. Reason for recall: CGMP Deviations: Presence of the N-nitroso-varenicline impurity above FDAs acceptable interim acceptable intake limit The recall status is ongoing. Affected quantity: 69,6396 bottles.

Recall details

Product Type
Drugs
Report Date
Aug 11, 2021
Initiation Date
Jun 9, 2021
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
69,6396 bottles

Product description

Chantix (varenicline) tablets, 1 mg, 56 Tablets, Rx Only, Distributed by Pfizer Labs, Division of Pfizer Inc., NY, NY 10017, Made in Ireland. NDC 0069-0469-56

Reason for recall

CGMP Deviations: Presence of the N-nitroso-varenicline impurity above FDAs acceptable interim acceptable intake limit

Distribution pattern

Nationwide

Code information

Lots EC9843, Exp 31, Mar 2023; EA6080, Exp. 31, Mar 2023.

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0701-2021
openFDA file date
Nov 19, 2026
Loaded by RegDataLab
Nov 20, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Need the full FDA record for Pfizer Inc.? Ask Claude or ChatGPT with the RegDataLab connector and get every site's inspections, Form 483s, warning letters, recalls and import alerts, each with a link to the FDA source. The API key is free: no card.

Get a free API key

How the connector works

Source: openFDA record for D-0701-2021. Report a data issue: hello@regdatalab.com.